Program
rilvegostomig
Also written as “Rilvegostomig”, “AZD2936” and “AZD9592 + Rilvegostomig”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Biliary Tract Neoplasms · Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Drug pageRilvegostomig: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 2222 open or running | phase 3since Oct 26, 2023 | Dec 13, 2018 | May 4, 2027phase 2 · NCT04379596 |
| Presage Biosciencesits history only | 21 open or running | early phase 1since Sep 1, 2020 | Sep 1, 2020 | Dec 2031early phase 1 · NCT04541108 |
- Named in AstraZeneca’s own pipeline as
rilvegostomig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 6 earlier studies, Dec 13, 2018 to Dec 7, 2022.
- Jul 21, 2022Named rilvegostomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, AZD2936
- Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularNCT05775159 · 294 enrolled · United States, China, Hong Kong and more
- Oct 26, 2023Phase 3 study in Biliary Tract NeoplasmsNCT06109779 · 760 enrolled · United States, Australia, Belgium and more
- Apr 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06357533 · 675 planned · United States, Australia, Austria and more
- May 21, 2024Phase 3 study in Biliary Tract NeoplasmsNCT06467357 · 620 planned · United States, Australia, Austria and more
- Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06564844 · 25 enrolled · United States, Brazil, Canada and more
- Oct 3, 20242 phase 3 studiesNCT06627647, NCT06692738
- Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerNCT06764875 · 840 planned · United States, Argentina, Australia and more
- Mar 7, 20253 phase 3 studiesNCT06868277, NCT06989112, NCT06921785
- May 5, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06996782 · 152 planned · United States, Belgium, Brazil and more
- Sep 3, 2025Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT07161414 · 40 planned · United States, South Korea, Spain and more
- Oct 1, 2025Phase 3 study in Biliary Tract NeoplasmsNCT07221253 · 1,100 planned · United States, Australia, Belgium and more
- Jan 16, 2026Phase 3 study in Stomach NeoplasmsNCT07431281 · 2,130 planned · United States, Australia, Austria and more
- Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellNCT07720284 · 915 planned · United States, Australia, Brazil and more
- Nov 10, 2026Primary completion moved from 2026-08-28 to 2028-06-01Date moved laterphase 2 · +21 months · NCT04995523
Ahead
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT04379596
- Jul 19, 2027Primary completion: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT07161414
- Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT05702229
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory …”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory mot”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
Studies
All 22 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more | 3 | Recruiting | Sep 11, 2030 | 915 |
| NCT07431281Stomach Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Aug 16, 2029 | 2,130 |
| NCT07221253Biliary Tract Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Jul 31, 2029 | 1,100 |
| NCT07161414Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, South Korea, Spain and more | 1 | Recruiting | Jul 19, 2027 | 40 |
| NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more | 2 | Recruiting | Feb 23, 2029 | 152 |
| NCT06921785Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Recruiting | Mar 15, 2030 | 1,220 |
| NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Jan 19, 2029 | 600 |
| NCT06868277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jan 17, 2030 | 830 |
| NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Apr 27, 2029 | 840 |
| NCT06692738Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jul 1, 2030 | 1,160 |
| NCT06627647Non-squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Nov 18, 2030 | 1,160 |
| NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more | 3 | Active, not recruiting | Jul 10, 2026 | 25 |
| NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Jun 12, 2028 | 620 |
| NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | Dec 28, 2029 | 675 |
| NCT06109779Biliary Tract Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jan 2, 2029 | 760 |
| NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | Oct 27, 2026 | 294 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | Nov 30, 2027 | 163 |
| NCT05123482Breast Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Sep 29, 2027 | 460 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | May 28, 2030 | 630 |
| NCT04995523Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Active, not recruiting | Jun 1, 2028 | 212 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | May 4, 2027 | 452 |
| NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 1 | Active, not recruiting | May 23, 2023 | 175 |
How it is read
Names in the registry
- “Rilvegostomig”, 20 entries
- “AZD2936”, 2 entries
- “AZD9592 + Rilvegostomig”, 2 entries
- “AZD8205 and AZD2936 (Rilvegostomig)”, 1 entry
- “AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Stomach Neoplasms, 4 studies
- Biliary Tract Neoplasms, 3 studies
- Carcinoma, Hepatocellular, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.